A Look Inside The White House’s First Cannabis Products Enforcement Policy Meeting
The White House has held the first in a series of scheduled meetings with cannabis industry and research stakeholders to discuss a proposed new enforcement policy for CBD products. Representatives of the Office of Information and Regulatory Affairs (OIRA) under the White House Office of Management and Budget (OMB) spoke with David Heldreth, CEO of […]
White House Schedules More Meetings On Cannabis Product Enforcement Policy From FDA For This Week
The White House now scheduled a total of four meetings with cannabis industry and research stakeholders this week to discuss a proposed enforcement policy for CBD products. The Office of Information and Regulatory Affairs (OIRA) under the White House Office of Management and Budget (OMB) announced earlier this month that it plans to review yet-unpublished guidance […]
White House Schedules Meeting On Cannabis Products Enforcement Policy For Next Week
The White House has scheduled a meeting for next week with a cannabis biotechnology company executive regarding a proposed enforcement policy for CBD products. The Office of Information and Regulatory Affairs (OIRA) under the White House Office of Management and Budget (OMB) announced earlier this month that it plans to review yet-unpublished guidance titled “Cannabidiol […]
Army adopts new cannabis policy to boost recruitment (Newsletter: March 26, 2026)
Federal bill could peg marijuana users as gang members; CA gov on legalization; AZ cannabis odor vote; DE medical use in hospitals; WA psychedelics Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Your support makes Marijuana […]
Meet the 19 Experts the UN Chose to Help Shape the Future of Drug Policy
The Commission on Narcotic Drugs’ new 19-member expert panel will help inform the UN’s 2029 global drug policy review, with potential consequences for cannabis regulation, harm reduction, treaty flexibility, and criminal justice reform worldwide. The United Nations’ Commission on Narcotic Drugs (CND) recently announced the participants of its newly established Expert Panel, whose purpose is […]
Marijuana Reform Isn’t This White House’s Drug Policy Priority
Sara Carter, the former investigative journalist and Fox News contributor now serving as White House drug czar, has spent her early months emphasizing fentanyl, trafficking and addiction, not marijuana reform. Cannabis may still move through federal channels, but it is clearly not the part of drug policy this White House wants to lead with. If […]
FDA Submits New Cannabis Products Enforcement Policy For White House Review
The Food and Drug Administration (FDA) has submitted a proposed cannabis products enforcement policy to the White House for review that concerns regulatory issues specifically related to CBD. The White House Office of Management and Budget’s (OMB) Office of Information and Regulatory Affairs (OIRA) posted a notice that it received the submission from FDA, which […]
Marijuana And Hemp Leaders Have Found Agreement On Many Significant Policy Issues (Op-Ed)
“With marijuana and hemp leaders working together toward a shared vision of more effective federal policy, the path ahead is brighter for the entire cannabinoid marketplace.” By Adam Rosenberg, National Cannabis Industry Association and Eric Berlin, Dentons Last fall, we wrote that marijuana and hemp businesses were working together as a group informally called the […]
New Cannabis Group Will Help Ground Policy In Science And Patient Experience As Trump’s Rescheduling Move Advances (Op-Ed)
“Federal policy must reflect evidence and science, not dispelled myths and tired stereotypes.” By Sasha Kalcheff-Korn, National Compassionate Care Council Recent federal action initiating a review of cannabis scheduling and signaling interest in expanding cannabinoid research reflects a growing willingness to examine how federal policy aligns with emerging evidence and real-world patient experience—but it also […]